CRISPR Therapeutics AG Form 4 Filings

CRISPR Therapeutics AG director George Simeon received a grant of stock options for 13,000 common shares. The options carry an exercise price of $51.84 per share and expire on June 5, 2036. This is a compensation-related award, not an open-market trade.

According to the vesting terms, the options vest in 12 equal monthly installments, subject to his continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.

CRISPR Therapeutics AG director Ali Behbahani received a new stock option grant covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. They were awarded as compensation rather than bought on the open market.

According to the vesting terms, the options vest in 12 equal monthly installments, with the first installment on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 annual meeting.

CRISPR Therapeutics AG director Maria Fardis received a grant of stock options, giving her the right to buy 13,000 common shares at an exercise price of $51.84 per share. These options were awarded as compensation, not through open-market buying or selling.

According to the vesting terms, the 13,000 options will vest in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 Annual Meeting, assuming she continues to provide service to the company or its subsidiaries.

CRISPR Therapeutics AG reported that director Harold Edward Fleming received a grant of stock options covering 13,000 common shares. The options have an exercise price of 51.84 per share and expire on June 5, 2036. Subject to continued service, they vest in 12 equal monthly installments, beginning with the first installment on June 30, 2026 and the last on the earlier of the one-year anniversary of the grant date or the 2027 annual meeting.

CRISPR Therapeutics AG director John Greene received a grant of stock options covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.

According to the vesting terms, the award vests in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the last installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.

CRISPR Therapeutics AG director Katherine A. High received a grant of 13,000 stock options on Common Shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. They vest in 12 equal monthly installments, beginning June 30, 2026, subject to continued service, with final vesting on the earlier of the one-year anniversary of grant or the 2027 Annual Meeting.

CRISPR Therapeutics AG reported that director Sandesh Mahatme received a grant of stock options covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.

According to the terms, the award vests in 12 equal monthly installments, subject to continued service, with the first installment vesting on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting. This is a compensation-related award rather than an open-market purchase or sale.

CRISPR Therapeutics AG director Morrison Briggs received a grant of stock options for 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.

According to the vesting terms, the options vest in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.

CRISPR Therapeutics AG director Christian Rommel received a grant of stock options for 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. This is a compensation-related award, not an open-market purchase or sale.

According to the vesting terms, the options will vest and become exercisable in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting, subject to his continued service.

CRISPR Therapeutics AG director Douglas A. Treco received a stock option grant covering 13,000 common shares. The option has an exercise price of $51.84 per share and was awarded at no purchase cost to him on the grant date.

The option expires on June 5, 2036. According to the vesting terms, it becomes exercisable in 12 equal monthly installments, with the first vesting on June 30, 2026 and the final installment vesting on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.

KASINGER JAMES R. reported acquisition or exercise transactions in this Form 4 filing.

CRISPR Therapeutics AG reported that its General Counsel and Secretary, James R. Kasinger, received a grant of 17,000 restricted stock units. Each unit represents a right to receive one common share. All 17,000 units are scheduled to vest on November 29, 2028, if the vesting conditions are met.

Patel Naimish reported acquisition or exercise transactions in this Form 4 filing.

CRISPR Therapeutics AG reported that Chief Medical Officer Naimish Patel received a grant of 22,000 restricted stock units. Each unit represents one common share. The award was granted as compensation on May 29, 2026, and all 22,000 units are scheduled to vest on November 29, 2028, subject to the usual conditions.

Prasad Raju reported acquisition or exercise transactions in this Form 4 filing.

CRISPR Therapeutics AG reported that its Chief Financial Officer, Prasad Raju, received a grant of 19,500 Restricted Stock Units on May 29, 2026. Each RSU represents a contingent right to receive one common share, so this award ties directly to future share ownership.

All 19,500 underlying common shares will vest in a single tranche on November 29, 2028, aligning the CFO’s compensation with the company’s long-term performance. Following this grant, the filing shows 19,500 derivative securities linked to common shares held directly.

CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported RSU vesting and a related share sale. On May 28, 10,000 Restricted Stock Units converted into 10,000 Common Shares at $0.00 per share. On May 29, 3,786 Common Shares were sold at $55.62 per share to cover tax withholding, as mandated by the company’s RSU Settlement Policy and described as non-discretionary. Following these transactions, Patel directly held 19,357 Common Shares. The underlying RSU award covers 40,000 shares, with 10,000-share tranches scheduled to vest annually from 2025 through 2028.

CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity grants, vesting, and a small share sale tied to taxes. He received a stock option for 38,499 Common Shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting on April 20, 2026. He was also granted 25,000 Restricted Stock Units (RSUs) that will vest in four annual installments of 6,250 shares each from March 20, 2027 through March 20, 2030.

On March 20, 2026, 6,250 RSUs from a prior 2024 grant vested and were converted into 6,250 Common Shares. On March 23, 2026, 3,182 Common Shares were sold at $46.78 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, Kasinger directly held 94,308 Common Shares, which remain subject to a lock-up agreement related to the company’s offering of convertible senior notes due 2031.

CRISPR Therapeutics CEO Samarth Kulkarni reported a mix of equity grants, vesting, and a small mandated share sale. On March 20, 2026, restricted stock units covering 19,687 Common Shares vested and were settled into shares, and he received a new stock option for 114,249 Common Shares at an exercise price of $46.24, plus a new restricted stock unit award for 81,875 Common Shares with vesting from 2027 through 2030.

On March 23, 2026, 10,020 Common Shares were sold at $46.78 per share solely to cover tax withholding tied to the RSU vesting, pursuant to the company’s RSU Settlement Policy and described as a non-discretionary transaction. After these events, Kulkarni held 255,501 Common Shares directly, and certain shares remain subject to a lock-up agreement related to the company’s convertible senior notes due 2031.

CRISPR Therapeutics AG Chief Financial Officer Prasad Raju reported a mix of equity awards, an option exercise, and a mandated share sale. On March 20, 2026, he received a stock option covering 38,499 Common Shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026. He was also granted 27,500 restricted stock units (RSUs), scheduled to vest in four annual tranches from March 20, 2027 through March 20, 2030.

On the same date, 6,250 RSUs from a prior 2024 award vested and were converted into 6,250 Common Shares. On March 23, 2026, Raju sold 3,708 Common Shares at an average price of $46.78 per share. A footnote states this sale was required to cover tax withholding on the RSU vesting under the company’s RSU Settlement Policy and "does not represent a discretionary trade". After these transactions, he directly held 15,565 Common Shares, which remain subject to a lock-up agreement related to the issuer’s convertible senior notes due 2031.

CRISPR Therapeutics AG granted equity awards to its Chief Medical Officer, Naimish Patel. On March 20, 2026, he received stock options covering 38,499 common shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026.

He was also awarded 30,000 restricted stock units, each representing one common share. These RSUs vest in four equal annual installments on March 20 of 2027, 2028, 2029 and 2030. Both awards are recorded as direct ownership and reflect compensation-related acquisitions rather than open-market purchases.

CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported routine equity compensation activity, including RSU vesting and a mandated tax-related sale. On March 14, 2026, 8,125 Restricted Stock Units converted into 8,125 Common Shares at $0.00 per share, representing the first quarter of a 32,500-share RSU grant awarded on March 14, 2025.

A separate footnote explains that 3,150 Common Shares were sold at $48.26 per share on March 16, 2026 solely to cover tax withholding obligations tied to this vesting, as required by the company’s RSU Settlement Policy, and that this did not represent a discretionary trade. Following these transactions, Patel directly owns 13,143 Common Shares, including 592 acquired under the 2016 Employee Stock Purchase Plan, and holds 24,375 unvested Restricted Stock Units that continue to vest annually through March 14, 2029.

CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised and vested restricted stock units and related common shares, then disposed of a portion mainly for tax obligations and a gift. On March 14, 2026, he acquired 16,875 common shares through the conversion of restricted stock units granted in 2023 and 2025. On March 16, 2026, 9,869 common shares were sold at $48.26 per share to satisfy tax withholding requirements under the company’s RSU Settlement Policy, and 750 shares were transferred as a bona fide gift without consideration. After these transactions, he directly held 13,023 common shares, which remain subject to a lock-up related to the company’s convertible senior notes due 2031.

CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported RSU vesting and a related share sale. On March 14, 2026, 6,875 restricted stock units converted into 6,875 common shares at $0.00 per share, as part of a 27,500-share RSU grant vesting annually from 2026 to 2029.

On March 16, 2026, he sold 3,450 common shares at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, he directly holds 91,240 common shares and 20,625 restricted stock units, with remaining shares subject to a lock-up agreement tied to the company’s convertible senior notes due 2031.

CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related tax sale. On March 14, 2026, 20,625 Restricted Stock Units vested and were converted into 20,625 Common Shares at a conversion price of $0.00 per share.

The vested RSUs are part of an 82,500-share award granted on March 14, 2025, scheduled to vest in four equal annual installments through March 14, 2029. On March 16, 2026, 10,349 Common Shares were sold at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnotes state does not represent a discretionary trade. After these transactions, Kulkarni directly holds 245,834 Common Shares and 61,875 Restricted Stock Units.

CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported an RSU vesting and related share sale. On March 10, 2026, he acquired 5,500 Common Shares at $0.00 per share through the exercise of Restricted Stock Units, reflecting part of a 22,000-share award granted on March 10, 2023.

On March 11, 2026, he sold 2,800 Common Shares at an average price of $52.80 per share. A footnote states these shares were sold to cover tax withholding obligations under the company’s RSU Settlement Policy and were not a discretionary trade. After these transactions, he directly owned 87,815 Common Shares.

CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported compensation-related share activity. On March 10, 2026, 19,250 restricted stock units were exercised into 19,250 Common Shares at $0.00 per share, reflecting vesting of part of a prior equity award.

On March 11, 2026, 9,798 Common Shares were sold at $52.80 per share. A footnote explains this amount was required to be sold to cover tax withholding tied to the RSU vesting under the company’s RSU Settlement Policy, and therefore did not represent a discretionary trade. After these transactions, Kulkarni directly held 235,558 Common Shares.

CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related share sale. On February 18, 2026, he acquired 13,250 Common Shares at $0.00 per share through the exercise/settlement of restricted stock units.

On February 19, 2026, he sold 6,967 Common Shares at an average price of $52.58 per share. A footnote explains that this sale was required to cover tax withholding obligations under the company’s RSU Settlement Policy and was not a discretionary trade. After these transactions, he directly held 226,106 Common Shares.

The restricted stock units were originally granted on February 18, 2022 for 53,000 Common Shares, vesting in four equal annual installments through February 18, 2026.

CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity transactions involving company stock. On February 18, 2026, he acquired 3,825 Common Shares through the exercise and settlement of restricted stock units at a price of $0.00 per share, increasing his direct holdings to 87,227 Common Shares. On February 19, 2026, 2,112 Common Shares were sold at an average price of $52.58 per share to cover tax withholding obligations related to the RSU vesting, as required by the company’s RSU Settlement Policy and not as a discretionary trade. After these transactions, he directly owned 85,115 Common Shares.

CRISPR Therapeutics’ Chief Medical Officer, Naimish Patel, reported buying 1,508 common shares at $32.96 each on April 3, 2025. This direct ownership transaction brought his total reported holdings to 1,508 shares.

The filing notes this purchase was matchable under Section 16(b) with a later sale of 1,508 shares at $35.94 per share on May 29, 2025 under a mandatory “sell to cover” for a vested restricted stock unit. Patel agreed to pay CRISPR Therapeutics $4,493.84, equal to the full short-swing profit.

CRISPR Therapeutics’ Chief Financial Officer Prasad Raju reported an option exercise and share sale. On January 22, 2026, he exercised a stock option for 34,972 Common Shares at an exercise price of $45.15 per share, acquiring the same number of common shares. That same day, he sold 34,972 Common Shares at a weighted average price of $60.19 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025. After these transactions, he directly held 6,767 Common Shares and 41,667 stock options.

CRISPR Therapeutics Chief Executive Officer and director Samarth Kulkarni reported multiple open-market sales of common shares under a pre-set Rule 10b5-1 trading plan adopted on August 27, 2025. On January 20, 2026, he sold 21,433 common shares at a weighted average price of $51.61 and 8,567 common shares at a weighted average price of $52.10. On January 22, 2026, he sold 60,000 common shares at a weighted average price of $60.23. Following these transactions, Kulkarni beneficially owns 134,201 common shares directly and 85,622 common shares indirectly through The Kulkarni 2023 GRAT.

CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised stock options for 29,700 Common Shares on January 6, 2026 at exercise prices of $45.15 and $44.31 per share, then sold 29,700 Common Shares at weighted average prices of $60.1799, $60.0000 and $60.2134 per share under a Rule 10b5-1 trading plan adopted on August 18, 2025. Following these transactions, he directly holds 84,132 stock options and 6,767 Common Shares.

CRISPR Therapeutics AG’s Chief Financial Officer, who files individually, reported automatic sales of company stock. On December 22, 2025, the officer sold a total of 10,000 common shares of CRISPR Therapeutics AG in three separate transactions, at weighted average prices of $55.1022, $56.3345, and $56.8858 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, which is designed to provide an affirmative defense for insiders trading under predetermined instructions. After these sales, the officer beneficially owns 6,767 common shares directly.

CRISPR Therapeutics (CRSP) Form 4: On October 16, 2025, the CEO and director reported the vesting and settlement of 100,000 restricted stock units into common shares. On October 17, 2025, 50,895 common shares were sold at $67.91 to cover tax withholding mandated by company policy. Following these transactions, holdings were 254,201 common shares directly and 85,662 indirectly via The Kulkarni 2023 GRAT. The RSU grant leaves 300,000 RSUs scheduled to vest annually through October 2028.

CRISPR Therapeutics (CRSP) reported an insider equity event. The company’s General Counsel and Secretary had 2,114 restricted stock units settle into common shares on 10/13/2025. On 10/14/2025, 1,076 shares were sold at $66.6 to cover tax withholding under the company’s RSU Settlement Policy, described as a non-discretionary sale.

Following these transactions, the insider directly owned 83,402 common shares. A remaining balance of 2,113 RSUs is reported outstanding.

CRISPR Therapeutics (CRSP) insider activity: The company’s Chief Executive Officer and Director reported the vesting of 8,334 restricted stock units on 10/13/2025, increasing direct holdings. On 10/14/2025, 4,242 common shares were sold at $66.6 to satisfy tax withholding mandated by the company’s RSU Settlement Policy.

Following these transactions, directly held common shares were 205,096, with an additional 85,662 held indirectly via The Kulkarni 2023 GRAT. The RSU grant was part of a 25,000‑share award vesting in three annual tranches.

CRISPR Therapeutics (CRSP) reported an insider equity award. The Chief Executive Officer and Director received a stock option covering 49,500 Common Shares on October 3, 2025 with an exercise price of $67.74 per share. The option vests in 48 equal monthly installments, beginning November 3, 2025, and expires on October 3, 2035. The filing lists the holding as Direct ownership.

CRISPR Therapeutics AG (CRSP) reported an insider equity award. The company’s Chief Medical Officer received a stock option covering 16,500 common shares with an exercise price of $67.74 on October 3, 2025. The option expires on October 3, 2035.

The award vests in 48 equal monthly installments, beginning November 3, 2025. Following the grant, 16,500 derivative securities were beneficially owned, shown as Direct (D) ownership.

CRISPR Therapeutics AG reported an insider transaction on Form 4 for its Chief Financial Officer. The filing discloses a stock option grant covering 16,500 Common Shares at an exercise price of $67.74 on October 3, 2025. The option vests in 48 equal monthly installments beginning November 3, 2025 and carries an expiration date of October 3, 2035. The reporting person holds 16,500 derivative securities directly following the transaction.

On 09/17/2025 Samarth Kulkarni, Chief Executive Officer and a Director of CRISPR Therapeutics AG (CRSP), reported a transaction on Form 4 showing he donated 6,000 common shares to a donor-advised fund. The Form 4 shows 201,004 shares beneficially owned directly after the transaction and 85,622 shares indirectly held through the Kulkarni 2023 GRAT. The filing is signed on 09/19/2025 and notes the donation as the reason for the disposition; the reported price is $0.00, indicating a charitable transfer rather than a sale for proceeds.